"This strategic endeavor represents a significant step forward in our commitment to advancing newborn health through innovative genomic technologies," said Yves Dubaquie, senior vice president, diagnostics at Revvity. "By combining our expertise in newborn screening and rare disease detection with Element’s technological capabilities, Revvity aims to deliver a robust, efficient, and accessible solution for neonatal sequencing in both research and clinical settings."